|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$2,796,386
|
N/A
|
National Institutes of Health
|
|
IGF::OT::IGF
|
261201800047C
|
$1,499,914
|
$1,499,914
|
-, -
|
CHARLES RIVER ANALYTICS, INC.
|
|
NATIONAL LONGITUDINAL MORTALITY STUDY (NLMS) AGREEMENT W/ CENSUS & DCCPS/DCEG
|
APC18001-001
|
$55,000
|
$55,000
|
-, -
|
CENSUS, UNITED STATES BUREAU O
|
|
NATIONAL CONFERENCE ON TOBACCO OR HEALTH
|
APC18003-001
|
$750
|
$750
|
-, -
|
CENTERS FOR DISEASE CONTROL &
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
$158,403
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
$6,583
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
$22,666
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Cancer Prevention and Control Health Disparities Training Program
|
5T32CA078447-18
|
$161,530
|
$32,306
|
ALBERTS, DAVID
|
UNIVERSITY OF ARIZONA
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
|
1R01CA222931-01A1
|
$370,575
|
|
AMENGUAL, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
$44,349
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Functional Contribution of Metabolic Complex to Cancer Cell Metabolism
|
1R03CA219609-01A1
|
$72,194
|
|
AN, SONGON
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
|
Developing Human Induced Pluripotent Stem Cell Precision Oncology Models
|
1R50CA233164-01
|
$155,981
|
|
ANASTASAKI, CORINA
|
WASHINGTON UNIVERSITY
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Resource stratified phased implementation frameworks to improve breast healthcare
|
1R13CA224776-01A1
|
$50,000
|
|
ANDERSON, BENJAMIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
|
3R01CA201124-03S1
|
$189,200
|
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Multiscale proteomics studies of DNA repair and genomic stability
|
1R50CA233182-01
|
$162,365
|
|
APARICIO CASADO, TOMAS
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
|
2R01CA160495-06A1
|
$370,500
|
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Development of an MRI-compatible, High-Frequency Irreversible Electroporation (H-FIRE) System for Non-thermal Ablation of Inoperable Brain Tumors
|
1R43CA233158-01
|
$244,498
|
|
ARENA, CHRISTOPHER
|
VOLTMED, INC.
|
|
COMPRENDO: Adaptation and Implementation of a Peer-Navigation Intervention to Improve Research Literacy and Diversity in Pediatric Leukemia Clinical Trials
|
1K08CA230306-01
|
$254,821
|
|
ARISTIZABAL, PAULA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Cancer Genetics of Short Telomere Syndromes
|
1R01CA225027-01A1
|
$530,521
|
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
|
2R01CA176745-07
|
$404,076
|
|
ARMSTRONG, SCOTT
|
DANA-FARBER CANCER INST
|
|
Predicting the Presence of Clinically Significant Prostate Cancer using Multiparametric MRI and MR-US Fusion Biopsy
|
1R21CA220352-01A1
|
$195,568
|
|
ARNOLD, COREY
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
|
1R01CA231219-01
|
$444,969
|
|
ARONSON, WILLIAM
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$2,485
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$1,715
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$33,345
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Role of HER2 mutations in breast cancer progression and response to targeted therapies
|
1R01CA224899-01A1
|
$382,641
|
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$7,481
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$74,400
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Dual Targeting Redox?active Gold(I) Therapeutics
|
1R15CA232765-01
|
$462,195
|
|
ARUMUGAM, KUPPUSWAMY
|
WRIGHT STATE UNIVERSITY
|
|
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications
|
1R01CA230516-01
|
$564,655
|
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$79,544
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$840
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$2,065
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$2,578
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeting Nodal/TGF-Beta pathway to inhibit invasion and growth of retinoblastoma
|
1R21CA229919-01
|
$213,694
|
|
ASNAGHI, LAURA
|
JOHNS HOPKINS UNIVERSITY
|
|
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles
|
1R43CA232778-01
|
$295,240
|
|
ASSOULINE, JOE
|
NANOMEDTRIX, LLC
|
|
Cone Beam Tomosynthesis Fluoroscopy for Image Guided Interventions
|
3R43CA228158-01A1S1
|
$50,000
|
|
ATRIA, CRISTIAN
|
NVIEW MEDICAL, INC.
|
Total relevant funding to Basic Behavioral and Social Science for this search: $79,436,127
|